RLIP76 Targeted Therapy for Kidney Cancer
详细信息 查看全文
- 作者：Sharad S. Singhal ; Jyotsana Singhal ; James Figarola ; David Horne…
- 关键词：chemotherapeutics ; drug ; resistance ; glutathione ; conjugate transport ; kidney cancer ; RLIP76
- 刊名：Pharmaceutical Research
- 出版年：2015
- 出版时间：October 2015
- 年：2015
- 卷：32
- 期：10
- 页码：3123-3136
- 全文大小：543 KB
- 参考文献：1.Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007;2:667s鈥?0s.CrossRef
2.Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S鈥?S.CrossRef PubMed
3.Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro D, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329鈥?3.PubMed Central CrossRef PubMed
4.Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. 2007;12:1404鈥?5.CrossRef PubMed
5.Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol. 2008;4:205鈥?3.CrossRef PubMed
6.Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006;6:350鈥?.CrossRef PubMed
7.Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008;75:1302鈥?2.PubMed Central CrossRef PubMed
8.Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol. 1996;156:506鈥?1.CrossRef PubMed
9.Awasthi S, Singhal SS, Srivastava SK, Zimniak P, Bajpai KK, Saxena M, et al. Adenosine triphosphate-dependent transport of doxorubicin, daunomyicn, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest. 1994;93:958鈥?5.PubMed Central CrossRef PubMed
10.Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione-conjugates and doxorubicin. Biochemistry. 2000;39:9327鈥?4.CrossRef PubMed
11.Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine-kinase signaling and drug-resistance. Int J Cancer. 2003;106:635鈥?6.CrossRef PubMed
12.Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res. 2005;65:991鈥?.PubMed
13.Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo J-H, Cunningham CC, et al. RLIP76 and cancer. Clin Cancer Res. 2008;14:4372鈥?.PubMed Central CrossRef PubMed
14.Lin JT, Sharma R, Grady JJ, Awasthi S. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells over-expressing p-glycoprotein. Drug Metab Dispos. 2001;29:103鈥?0.PubMed
15.Bankhead C. Three new drugs available to fight kidney cancer. J Natl Cancer Inst. 2006;98:1181鈥?.CrossRef PubMed
16.Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43鈥?006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597鈥?12.CrossRef PubMed
17.Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477鈥?0.CrossRef PubMed
18.Brugarolas J. Renal-cell carcinoma鈥攎olecular pathways and therapies. N Engl J Med. 2007;356:185鈥?.CrossRef PubMed
19.Singhal SS, Yadav S, Roth C, Singhal J. RLIP76: a novel glutathione-conjugate and multi-drug transporter. Biochem Pharmacol. 2009;77:761鈥?.PubMed Central CrossRef PubMed
20.Vatsyayan R, Lelsani P, Awasthi S, Singhal SS. RLIP76: a versatile transporter and an emerging target for cancer therapy. Biochem Pharmacol. 2010;79:1699鈥?05.PubMed Central CrossRef PubMed
21.Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S. RLIP76: a target for kidney cancer therapy. Cancer Res. 2009;69:4244鈥?1.PubMed Central CrossRef PubMed
22.Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Lelsani P, et al. RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010;126:1327鈥?8.PubMed Central PubMed
23.Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia. 2010;12:1003鈥?2.CrossRef PubMed
24.Lee S, Wurtzel JG, Singhal SS, Awasthi S, Goldfinger LE. RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. Cancer Res. 2012;72:5165鈥?3.PubMed Central CrossRef PubMed
25.Mollberg NM, Steinert G, Aigner M, Hamm A, Lin F-J, Elbers H. Over-expression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse. Cancer Biol Ther. 2012;1:694鈥?00.CrossRef
26.Goldfinger LE, Lee S. Emerging treatments in lung cancer鈥攖argeting the RLIP76 molecular transporter. Lung Cancer. 2013;4:61鈥?.
27.Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu YC, et al. RLIP76 is over-expressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. Carcinogenesis. 2013;34:916鈥?6.CrossRef PubMed
28.Wang Q, Qian J, Wang JY, Luo C, Chen J, Hu G, et al. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J Neurooncol. 2013;112:73鈥?2.CrossRef PubMed
29.Zhang Y, Song X, Gong W, Zhu Z, Liu X, Hou Q, et al. RLIP76 blockade by siRNA inhibits proliferation, enhances apoptosis, and suppresses invasion in HT29 colon cancer cells. Cell Biochem Biophys. 2015;71:579鈥?5.CrossRef PubMed
30.Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol. 2006;11:209鈥?3.CrossRef PubMed
31.Sj枚lund J, Bostr枚m AK, Lindgren D, Manna S, Moustakas A, Ljungberg B, et al. The notch and TGF-尾 signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One. 2011;6, e23057.PubMed Central CrossRef PubMed
32.Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992鈥?000.CrossRef PubMed
33.Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271鈥?1.CrossRef PubMed
34.Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer F, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917鈥?0.CrossRef PubMed
35.Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev. 2006;16:78鈥?4.CrossRef PubMed
36.Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859鈥?0.PubMed Central CrossRef PubMed
37.Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9鈥?9.CrossRef PubMed
38.Singhal SS, Sehrawat A, Metha A, Sahu M, Awasthi S. Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugate. Int J Oncol. 2009;34:191鈥?.PubMed Central CrossRef PubMed
39.Sarkadi B, Homolya L, Szak谩cs G, V谩radi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemo-immunity defense system. Physiol Rev. 2006;86:1179鈥?36.CrossRef PubMed
40.Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999;1461:347鈥?7.CrossRef PubMed
41.Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, Nadkar A, et al. RALBP1 is a major determinant of radiation sensitivity. Cancer Res. 2005;65:6022鈥?.CrossRef PubMed
42.Singhal J, Singhal SS, Yadav S, Warnke M, Yacoub A, Dent P, et al. RLIP76 in defense of radiation poisoning. Int J Radiat Oncol Biol Phys. 2008;72:553鈥?1.PubMed Central CrossRef PubMed
43.Warnke MM, Wanigasekara E, Singhal SS, Singhal J, Awasthi S, Armstrong DW. The determination of glutathione-4-hydroxynonenal (GS-HNE), E-4-hydroxynonenal (HNE), and E-1-hydroxynon-2-en-4-one (HNO) in mouse liver tissue by LC-ESI-MS. Analyt Bioanal Chem. 2008;392:1325鈥?3.CrossRef
44.Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA. Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta. 1993;1164:173鈥?.CrossRef PubMed
45.Singhal SS, Yadav S, Singhal J, Sahu M, Sehrawat A, Awasthi S. Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76. FEBS Lett. 2008;582:3408鈥?4.PubMed Central CrossRef PubMed
46.Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor P, Awasthi YC, et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (RALBP1). Cancer Res. 2007;67:4382鈥?.CrossRef PubMed
47.Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 2006;66:2354鈥?0.CrossRef PubMed
48.Singhal SS, Roth C, Leake K, Singhal J, Yadav S, Awasthi S. Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol. 2009;77:1074鈥?3.PubMed Central CrossRef PubMed
49.Singhal J, Yadav S, Nagaprashantha L, Vatsyayan R, Singhal SS, Awasthi S. Targeting p53 null neuroblastomas through RLIP76. Cancer Prev Res. 2011;4:879鈥?9.CrossRef
50.Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445鈥?00.CrossRef PubMed
51.Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81鈥?28.CrossRef PubMed
52.Awasthi YC, Sharma R, Sharma A, Yadav S, Singhal SS, Chaudary P, et al. Self-regulatory role of 4-HNE in signaling for stress-induced programmed cell death. Free Radic Biol Med. 2008;45:111鈥?.PubMed Central CrossRef PubMed
53.Kramer MA, Tracy TS. Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol. 2008;4:591鈥?03.CrossRef PubMed
54.Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med. 1997;3:1275鈥?.CrossRef PubMed
55.Yamaguchi A, Urano T, Goi T, Feig LA. An eps homology (EH) domain protein that binds to the Ral-GTPase target, RalBP1. J Biol Chem. 1997;272:31230鈥?.CrossRef PubMed
56.Jullien-Flores V, Mahe Y, Mirey G, Leprince C, Meunier-Bisceuil B, Sorkin A, et al. RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. J Cell Sci. 2000;113:2837鈥?4.PubMed
57.Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, Vatsyayan R, et al. Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Ther. 2011;10:16鈥?8.PubMed Central CrossRef PubMed
58.Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicin resistance: doxorubicin transport in lung cancer by RLIP76. Int J Oncol. 2003;22:713鈥?0.PubMed
59.Awasthi S, Singhal SS, Singhal J, Yang Y, Zimniak P, Awasthi YC. Role of RLIP76 in lung cancer doxorubicin resistance: anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int J Oncol. 2003;22:721鈥?2.PubMed
60.Jullien-Flores V, Dorseuil O, Romero F, Letourneur F, Saragosti S, Berger R, et al. Bridging Ral GTPase to Rho pathways. RLIP, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem. 1995;270:22473鈥?.CrossRef PubMed
61.Rosse C, L鈥橦oste S, Offner N, Picard A, Camonis JH. RLIP, an effector of the Ral-GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem. 2003;278:30597鈥?04.CrossRef PubMed
62.Hu Y, Mivechi NF. HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multi-protein complex with HSP90 in vivo. J Biol Chem. 2003;278:17299鈥?06.CrossRef PubMed
63.Singhal SS, Yadav S, Singhal J, Zajac E, Drake K, Awasthi YC, et al. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol. 2005;70:481鈥?.CrossRef PubMed
64.Singhal SS, Yadav S, Singhal J, Drake K, Awasthi YC, Awasthi S. The role of PKC伪 and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. FEBS Lett. 2005;579:4635鈥?1.CrossRef PubMed
65.Sharma R, Singhal SS, Wickramarachchi D, Awasthi YC, Awasthi S. RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance. Int J Cancer. 2004;112:934鈥?2.CrossRef PubMed
66.Yadav S, Singhal SS, Singhal J, Wickramarachchi D, Kuntson E, Albrecht TB, et al. Identification of membrane anchoring domains of RLIP76 using deletion mutants analyses. Biochemistry. 2004;43:16243鈥?3.CrossRef PubMed
67.Oosterhoff JK, Penninkhof F, Brinkmann AO, Anton Grootegoed J, Blok LJ. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene. 2003;22:2920鈥?.CrossRef PubMed
68.Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem. 2008;283:19714鈥?9.PubMed Central CrossRef PubMed
69.Park SH, Weinberg RA. A putative effector of Ral has homology to Rho/Rac GTPase-activating proteins. Oncogene. 1995;11:2349鈥?5.PubMed
70.Cantor SB, Urano T, Feig LA. Identification and characterization of Ral-binding-protein 1, a potential downstream target of Ral GTPases. Mol Cell Biol. 1995;15:4578鈥?4.PubMed Central PubMed
71.Singhal SS, Awasthi S. Glutathione-conjugate transport and stress-response signaling: role of RLIP76. In: Awasthi YC, editor. Toxicology of glutathione S-Transferases. Boca Raton: CRC Press; 2006. p. 231鈥?6.CrossRef
72.Patel PH, Chadalavada RSV, Chaganti RSK, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215鈥?0.CrossRef PubMed
73.Kaelin WG. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;11:865鈥?3.CrossRef
74.Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci. 2000;97:10430鈥?.PubMed Central CrossRef PubMed
75.Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423鈥?.CrossRef PubMed
76.Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000鈥?1.CrossRef PubMed
77.Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci. 1998;95:8817鈥?2.PubMed Central CrossRef PubMed
78.Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991鈥?004.CrossRef PubMed
79.Ohh M, Kaelin WG. VHL and kidney cancer. Methods Mol Biol. 2003;222:167鈥?3.PubMed
80.Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677鈥?5.CrossRef PubMed
81.Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006;60:216鈥?6.CrossRef PubMed
82.Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res. 2004;10:794鈥?01.CrossRef PubMed
83.Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res. 2006;66:5130鈥?2.CrossRef PubMed
84.Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol. 2004;171:1309鈥?3.CrossRef PubMed
85.Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, et al. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res. 2006;12:3470鈥?.CrossRef PubMed
86.Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, et al. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res. 2007;67:11668鈥?6.CrossRef PubMed
87.Sj枚lund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008;118:217鈥?8.PubMed Central CrossRef PubMed
88.Yao K, Xing H, Yang W, Liao A, Wu B, Li Y, et al. Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemo-sensitivity to daunorubicin in U937 leukemia cells. Tumor Biol. 2014;35:8023鈥?1.CrossRef
89.Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, et al. RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol. 2007;30:139鈥?4.PubMed
90.Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, et al. Expression of Ral GTPases, their effectors and activators in human bladder cancer. Clin Cancer Res. 2007;13:3803鈥?3.CrossRef PubMed
91.Herlevsen MC, Theodorescu D. Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). Biochem Biophys Res Commun. 2007;362:56鈥?2.PubMed Central CrossRef PubMed
92.Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci. 2007;104:17494鈥?.PubMed Central CrossRef PubMed - 作者单位：Sharad S. Singhal (1)
Jyotsana Singhal (1)
James Figarola (1)
David Horne (2)
Sanjay Awasthi (1) (3)
1. Department of Diabetes & Metabolic Diseases Research, City of Hope, Comprehensive Cancer Center, Duarte, California, 91010, USA
2. Department of Molecular Medicine, City of Hope, Comprehensive Cancer Center, Duarte, California, 91010, USA
3. Department of Medical Oncology, Beckman Research Institute, City of Hope, Comprehensive Cancer Center, Duarte, California, 91010, USA - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Pharmacy
Biochemistry
Medical Law
Biomedical Engineering - 出版者：Springer Netherlands
- ISSN：1573-904X
文摘